Bumetanide Versus Furosemide in Heart Failure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00372762 |
Recruitment Status :
Withdrawn
(Due to changes within the research program this study is not feasible at this time)
First Posted : September 7, 2006
Last Update Posted : March 27, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Heart Failure | Drug: Furosemide Drug: Bumetanide Drug: furosemide Drug: bumetanide | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Bumetanide Has a More Favourable Effect on Insulin Resistance Than Furosemide in Patients With Heart Failure - A Pilot Study |
Study Start Date : | January 2011 |
Estimated Primary Completion Date : | January 2013 |
Estimated Study Completion Date : | June 2013 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Furosemide
Patients will be assigned to furosemide therapy (20mg to 80mg) orally, once or twice daily for an 8-week period.
|
Drug: Furosemide
Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
Other Name: Lasix Drug: furosemide 20mg to 80mg orally once or twice daily
Other Name: Lasix |
Active Comparator: Bumetanide
Patients will be assigned to bumetanide therapy at an equipotent dose to furosemide therapy (1mg bumetanide is equivalent to 40mg furosemide)for an 8-week period.
|
Drug: Bumetanide
Equivalent dose to pre-existing furosemide will be used
Other Names:
Drug: bumetanide 0.5mg to 2mg orally once or twice daily
Other Names:
|
- Insulin resistance, as determined by frequently sampled intravenous glucose tolerance test with minimal model analysis (FSIGT MINMOD) [ Time Frame: 3 months ]
- Fasting blood glucose [ Time Frame: 3 months ]
- Glycosylated hemoglobin (HbA1c) [ Time Frame: 3 months ]
- Serum creatinine, sodium, potassium, and chloride [ Time Frame: 3 months ]
- Submaximal exercise capacity as determined by the 6-minute walk test [ Time Frame: 3 months ]
- New York Heart Association Function Class heart failure (NYHA FC) [ Time Frame: 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men and women ≥18 years of age
- NHYA FC II or III HF AND documented LVEF ≤40% within 6 months prior to study entry
- Taking 20 mg to 80 mg furosemide orally once or twice per day
- No changes to cardiac medications for 3 months prior to study entry and no anticipated changes of medications for the duration of the study
- No changes to oral anti-diabetic medications (if applicable) for 3 months prior to study entry, and no anticipated changes for the duration of the study (metformin, sulphonylurea type, glitazone type)
- Ability to provide written consent
Exclusion Criteria:
- Known sensitivity to bumetanide
- Myocardial infarction, coronary angioplasty, coronary artery bypass surgery, admission for HF or unstable angina within a 3 month period prior to study recruitment
- Planned coronary intervention within 6 months
- Patients who are taking insulin
- Patients with chronic renal (serum creatinine ≥ 200 μmol/L) or hepatic impairment (known cirrhosis or AST or ALT > 1.5 x upper limit of normal)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00372762
Canada, Ontario | |
University Hospital, London Health Sciences Centre | |
London, Ontario, Canada, N6A 5A5 |
Principal Investigator: | Neville G Suskin, MBChB, MSc | LHSC, University of Western Ontario |
Responsible Party: | Neville Suskin, Principal Investigator, Lawson Health Research Institute |
ClinicalTrials.gov Identifier: | NCT00372762 |
Other Study ID Numbers: |
R-06-415 |
First Posted: | September 7, 2006 Key Record Dates |
Last Update Posted: | March 27, 2014 |
Last Verified: | March 2014 |
Insulin resistance heart failure diuretic therapy |
Heart Failure Heart Diseases Cardiovascular Diseases Furosemide Bumetanide Diuretics |
Natriuretic Agents Physiological Effects of Drugs Sodium Potassium Chloride Symporter Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |